Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Cheniere Energy (LNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Cheniere Energy — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Cheniere Energy trades at $280.95 (market cap $59.26B). The key difference: Cheniere Energy is far larger — about 6.7× Kymera Therapeutics Inc. Common Stock's market cap, and Cheniere Energy pays a 0.77% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Cheniere Energy for 12 Days on average.
| KYMR | LNG | |
|---|---|---|
Market Cap | $8.87B | $59.26B |
Volume | 779,107 | 1,056,751 |
Sector | Health | Energy |
52-Week High | $127.31 | $296.91 |
52-Week Low | $55.80 | $188.83 |
Typical Hold Time | 0 Days | 12 Days |
Enterprise Value | $8.26B | $84.72B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Cheniere Energy (LNG) trades at $286.92, up 1.57% on the day, with a bullish technical signal from moving averages. The stock exhibits strong profitability with a 45.23% ROE and 13.57% net income margin, though Q1 2026 earnings missed expectations. Recent news highlights the company's long-term growth through a 22-year LNG supply deal with Petrobras, supporting its position in the energy sector.
The outlook is positive with a consensus price target of $307.44, representing 7.2% upside potential. Risks include earnings volatility and capital expenditure demands from growth projects. Analyst sentiment is overwhelmingly bullish with 92.59% buy ratings, but investors should monitor execution on expansion initiatives and energy market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Cheniere Energy
Cheniere Energy produces, liquefies, and exports natural gas as liquefied natural gas, or LNG. It operates large-scale LNG infrastructure along the U.S. Gulf Coast.
Read more on LNG →
